These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 27004803)

  • 1. ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.
    Vilarrasa E; Notario J; Bordas X; López-Ferrer A; Gich IJ; Puig L
    J Am Acad Dermatol; 2016 Jun; 74(6):1066-72. PubMed ID: 27004803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Warren RB; Smith CH; Yiu ZZN; Ashcroft DM; Barker JNWN; Burden AD; Lunt M; McElhone K; Ormerod AD; Owen CM; Reynolds NJ; Griffiths CEM
    J Invest Dermatol; 2015 Nov; 135(11):2632-2640. PubMed ID: 26053050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population.
    Doshi JA; Takeshita J; Pinto L; Li P; Yu X; Rao P; Viswanathan HN; Gelfand JM
    J Am Acad Dermatol; 2016 Jun; 74(6):1057-1065.e4. PubMed ID: 26946986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.
    Cozzani E; Wei Y; Burlando M; Signori A; Parodi A
    J Am Acad Dermatol; 2020 Jan; 82(1):37-44. PubMed ID: 31150706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
    Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
    Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study.
    Kim WB; Marinas JE; Qiang J; Shahbaz A; Greaves S; Yeung J
    J Am Acad Dermatol; 2015 Aug; 73(2):237-41. PubMed ID: 26026334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival rates of biological therapies for psoriasis treatment in real-world clinical practice: A Canadian multicentre retrospective study.
    Marinas JE; Kim WB; Shahbaz A; Qiang JK; Greaves S; Yeung J
    Australas J Dermatol; 2018 Feb; 59(1):e11-e14. PubMed ID: 27858976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
    Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
    Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital.
    Sanz-Gil R; Pellicer A; Montesinos MC; Valcuende-Cavero F
    J Dermatolog Treat; 2020 Jun; 31(4):370-377. PubMed ID: 30924390
    [No Abstract]   [Full Text] [Related]  

  • 13. A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.
    Núñez M; Huete T; de la Cueva P; Sacristán JA; Hartz S; Dilla T
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):546-553. PubMed ID: 30851873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
    Verma L; Mayba JN; Gooderham MJ; Verma A; Papp KA
    J Cutan Med Surg; 2018; 22(1):38-43. PubMed ID: 29056080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis.
    Nast A; Jacobs A; Rosumeck S; Werner RN
    J Invest Dermatol; 2015 Nov; 135(11):2641-2648. PubMed ID: 26046458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.
    Jacobi A; Rustenbach SJ; Augustin M
    Int J Dermatol; 2016 Mar; 55(3):296-302. PubMed ID: 26470689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective observational study on biological drug treatment in a daily practice serving patients with psoriasis in Japan.
    Ohata C; Ohyama B; Nanri A; Shintani T; Nakama T
    J Dermatolog Treat; 2019 Feb; 30(1):45-48. PubMed ID: 29676591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.